OncoSpherix News & Events
OncoSpherix Holds Strategic Leadership and Scientific Review Meeting in Preparation for Key 2026/2027 Milestones
November 4, 2025 Integrated Cross-Functional Review Strengthens Readiness for IND-Enabling Completion and Clinical Entry Atlanta, GA — November 2025 — OncoSpherix, a biotechnology company advancing novel therapeutics targeting hypoxia-related oncogenic mechanisms,...
Loss of Dr. Harvey Golomb, OncoSpherix Advisory Board Member
It is with great sadness that OncoSpherix announces the passing of Dr. Harvey Golomb, a member of OncoSpherix’s clinical advisory board. Dr. Golomb was the Lowell T. Coggeshall Professor and former Chair of the Department of Medicine at the University of Chicago. He...
OncoSpherix Named Finalist for 2025 BIO International Convention Start-Up Stadium
May 13, 2025 Emerging oncology innovator OncoSpherix to showcase breakthrough cancer therapies at global biotech stage in Boston Atlanta, GA — May 2025 — OncoSpherix, a pre-clinical-stage oncology company advancing novel therapies for unresectable and metastatic...
OncoSpherix Selected to Present at Portal Innovations’ ‘Rising Stars in Oncology’ Event During AACR 2025
April 22, 2024 OncoSpherix to Showcase Breakthrough Oncology Innovations at Premier Biotech Event Atlanta, GA – Apr 2025 – OncoSpherix, a biotech company pioneering innovative therapies for tumor hypoxia, is excited to announce its participation in Portal Innovations’...
OncoSpherix Relocates to Portal Innovations’ State-of-the-Art Life Sciences Facilities, Poised for Next Stage of Growth
November 20, 2024 OncoSpherix Becomes a Portal Innovations Member Company Atlanta, GA – Nov 2023 – OncoSpherix,, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, is excited to announce its recent...
OncoSpherix Showcased at 2024 Georgia Bio Life Sciences Summit, Highlights Latest Advances in Cancer treatment
November 18, 2024 OncoSpherix Participates in Annual Georgia Life Sciences Summit Atlanta, GA – Nov 18, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, proudly participated in...
OncoSpherix expands its operations team with the appointment of Joseph Ellis, Ph.D., as Research Scientist
Oct 1, 2024 Joseph Ellis, Ph.D., joins OncoSpherix’s Research Team Atlanta, GA – Oct 1, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, announces the appointment of Joseph Ellis,...
OncoSpherix Presents at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM.
October 16, 2023 Atlanta, GA – October 16, 2023 – The CEO of OncoSpherix, Inc, Dr. Margaret K. Offermann, MD, PhD, is delivering a keynote address at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM. Her presentation...
OncoSpherix expands leadership team with the appointment of Allan Valmonte, M.B.A., as Vice President of Business Operations
April 28, 2023 Allan Valmonte, M.B.A., former Executive Director, Program Management Office (PMO) at Taysha Gene Therapies, joins OncoSpherix with over 25 years of program/portfolio management and clinical operations experience in the biotechnology and pharmaceutical...
OncoSpherix expands leadership team with the appointment of Steve Coats, Ph.D. as Vice President of Chemistry
April 28, 2023 Dr. Steve Coats, former Senior Director of Chemistry at Cocrystal Pharma, joins OncoSpherix with over 25 years of drug discovery and development experience in biotechnology and large pharmaceutical companies. Atlanta, GA – April 28, 2023 – OncoSpherix,...